Mena-Vazquez, NataliaGarcia-Studer, AimaraRojas-Gimenez, MartaRomero-Barco, Carmen MariaManrique-Arija, SaraMucientes, ArkaitzVelloso-Feijoo, Maria LuisaGodoy-Navarrete, Francisco JavierMorales-Garrido, PilarRedondo-Rodriguez, RocioOrdoñez-Cañizares, M COrtega-Castro, RafaelaLisbona-Montañez, Jose ManuelHidalgo Conde, AnaArnedo Diez de Los Rios, RocioCabrera Cesar, EvaEspildora, FranciscoAguilar-Hurtado, Maria CarmenAñón-Oñate, IsabelUreña-Garnica, InmaculadaFernandez-Nebro, Antonio2023-05-032023-05-032022-04-24Mena-Vázquez N, García-Studer A, Rojas-Gimenez M, Romero-Barco CM, Manrique-Arija S, Mucientes A, et al. Importance of Vaccination against SARS-CoV-2 in Patients with Interstitial Lung Disease Associated with Systemic Autoimmune Disease. J Clin Med. 2022 Apr 26;11(9):24372077-0383http://hdl.handle.net/10668/21278Objectives: To describe the frequency of COVID-19 and the effect of vaccination in patients with interstitial lung disease and systemic autoimmune disease (ILD-SAD) and to identify factors associated with infection and severity of COVID-19. Methods: We performed a cross-sectional multicenter study of patients with ILD-SAD followed between June and October 2021. The main variable was COVID-19 infection confirmed by a positive polymerase chain reaction (PCR) result for SARS-CoV-2. The secondary variables included severity of COVID-19, if the patient had to be admitted to hospital or died of the disease, and vaccination status. Other variables included clinical and treatment characteristics, pulmonary function and high-resolution computed tomography. Two logistic regression was performed to explore factors associated with “COVID-19” and “severe COVID-19”. Results: We included 176 patients with ILD-SAD: 105 (59.7%) had rheumatoid arthritis, 49 (27.8%) systemic sclerosis, and 22 (12.54%) inflammatory myopathies. We recorded 22/179 (12.5%) SARS-CoV-2 infections, 7/22 (31.8%) of them were severe and 3/22 (13.22%) died. As to the vaccination, 163/176 (92.6%) patients received the complete doses. The factors associated with SARS-CoV-2 infection were FVC (OR (95% CI), 0.971 (0.946−0.989); p = 0.040), vaccination (OR (95% CI), 0.169 (0.030−0.570); p = 0.004), and rituximab (OR (95% CI), 3.490 (1.129−6.100); p = 0.029). The factors associated with severe COVID-19 were the protective effect of the vaccine (OR (95% CI), 0.024 (0.004−0.170); p< 0.001) and diabetes mellitus (OR (95% CI), 4.923 (1.508–19.097); p = 0.018). Conclusions: Around 13% of patients with ILD-SAD had SARS-CoV-2 infection, which was severe in approximately one-third. Most patients with severe infection were not fully vaccinated.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/SARS-CoV-2 infectionsInterstitial lung disease (ILD)Systemic autoimmune disease (SAD)Vaccination COVID-19Área de Gestión Sanitaria Sur de SevillaHospitalsArthritis, rheumatoidScleroderma, systemicPolymerase chain reactionDiabetes mellitusAutoimmune diseasesTomographyresearch article35566564open accessArtritis reumatoideDiabetes mellitusEnfermedades autoinmunesEsclerodermia sistémicaHospitalesReacción en cadena de la polimerasaTomografía10.3390/jcm11092437PMC9106041https://www.mdpi.com/2077-0383/11/9/2437/pdf?version=1650976770https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9106041/pdf